{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:57:08Z","timestamp":1791932228792,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hospitalizations for adverse drug reactions (ADR\u2010HA) have increased over the last decade, but the impact of ADR\u2010HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR\u2010HA in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR\u2010HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group\u2010based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3\u2009months as from the first day of ADR\u2010HA). The robustness of the results was assessed using a one\u2010way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to the 2018 tariffs (\n                      <jats:italic>vs<\/jats:italic>\n                      . 2023), the mean total cost per patient with ADR\u2010HA was estimated at \u20ac5208\u2009\u00b1\u2009\u20ac3719 (\n                      <jats:italic>vs<\/jats:italic>\n                      . \u20ac5974\u2009\u00b1\u2009\u20ac4232) ranging from \u20ac514 to \u20ac23\u2009355 (\n                      <jats:italic>vs<\/jats:italic>\n                      . \u20ac618 to \u20ac27\u2009380). The total cost for 196 patients with ADR\u2010HA admitted to a sample of French public hospitals was estimated at \u20ac1\u2009020\u2009549 (\n                      <jats:italic>vs<\/jats:italic>\n                      . \u20ac1\u2009170\u2009960). It could be estimated at \u20ac1.3 billion at the national level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR\u2010HA weighs heavily on healthcare spending.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.16266","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:50:05Z","timestamp":1728010205000},"page":"439-450","source":"Crossref","is-referenced-by-count":21,"title":["Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT\u2010ECO study"],"prefix":"10.1111","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-0359","authenticated-orcid":false,"given":"Marie\u2010Laure","family":"Laroche","sequence":"first","affiliation":[{"name":"Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology\u2010Toxicology and Pharmacovigilance CHU Limoges  Limoges France"},{"name":"UR 24134 (VieSant\u00e9\u2010Vieillissement, Fragilit\u00e9, Pr\u00e9vention, e\u2010Sant\u00e9), IFR OMEGA HEALTH Universit\u00e9 de Limoges  Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Tarbouriech","sequence":"additional","affiliation":[{"name":"P\u00f4le Pharmacie CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Jai","sequence":"additional","affiliation":[{"name":"P\u00f4le Pharmacie CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-5733","authenticated-orcid":false,"given":"Marie\u2010Blanche","family":"Valnet\u2010Rabier","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance et d'information sur le m\u00e9dicament CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-6040","authenticated-orcid":false,"given":"Virginie","family":"Nerich","sequence":"additional","affiliation":[{"name":"CHU Besan\u00e7on, INSERM, EFS\u2010BFC, UMR 1098, P\u00f4le Pharmacie Universit\u00e9 de Franche\u2010Comt\u00e9  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12293"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100444\u20107"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010017\u20102225\u20103"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010015\u20100281\u20100"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15510"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12088"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S115689"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1491547"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.3.319"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000260"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050738"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13613\u2010016\u20100109\u20109"},{"key":"e_1_2_11_14_1","volume-title":"Choices in methods for economic evaluation","author":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"e_1_2_11_15_1","volume-title":"International statistical classification of diseases and related health problems, ICD\u201010","author":"World Health Organization","year":"2016"},{"key":"e_1_2_11_16_1","volume-title":"Classification commune des actes m\u00e9dicaux en ligne","author":"Assurance Maladie"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010199920020\u201000002"},{"key":"e_1_2_11_18_1","volume-title":"Guidelines for anatomical therapeutic chemical (ATC) classification system and defined daily dose (DDD) assignment","author":"World Health Organization Collaborating Centres"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2004.09.011"},{"key":"e_1_2_11_20_1","volume-title":"Discrete multivariate analysis theory and practice","author":"Yvonne M","year":"2007"},{"key":"e_1_2_11_21_1","volume-title":"Les d\u00e9penses de sant\u00e9 en 2022\u2014R\u00e9sultats des comptes de la sant\u00e9 (Table 1, page 39)\u2014\u00c9dition 2023"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.007"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010023\u201003552\u2010x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536800\u2010000000000\u201000000"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102022\u2010062589"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1981863"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S304074"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.014"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47909"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12189"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200022020\u201000007"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2010.09.001"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.12.007"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T02:07:31Z","timestamp":1738030051000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/bcp.16266"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16266","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}